newsfilter
← Latest News
GlobeNewswire·

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

  • FibroBiologics, Inc. (NASDAQ: FBLG) announced preclinical data presentation for its CYPS317 psoriasis program at the Society for Investigative Dermatology 2026 Annual Meeting in Chicago, Illinois.
  • The meeting is scheduled to occur from May 13-15, 2026, with the specific session taking place on May 15, 2026, from 4:30 p.m. to 6 p.m. CT.
  • Chuo Fang, MD, Ph.D., Senior Scientist at FibroBiologics, will present the data in Salons B, C, D on the 3rd Floor at the Williford venue.
  • FibroBiologics is a Houston-based clinical-stage biotechnology company developing therapeutics & potential cures for chronic diseases using fibroblast cells & fibroblast-derived materials.
  • The company holds 270+ issued & pending patents covering clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, & cancer.
  • General inquiries can be directed to info@fibrobiologics.com, while investor & media contacts are handled by Russo Partners.